Biosimilar switch safe and effective for inflammatory diseases
NCT ID NCT02998398
First seen Jan 16, 2026 · Last updated May 16, 2026 · Updated 16 times
Summary
This study checked whether patients with rheumatoid arthritis, spondyloarthritis, Crohn's disease, or uveitis could safely switch from the original drug Remicade to its lower-cost biosimilar Inflectra. Researchers followed 262 adults at one hospital who had already received at least three doses of Remicade. They measured how many patients stayed on Inflectra after three infusions and looked for disease flares or changes in drug levels.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hôpital Cochin
Paris, Paris, 75014, France
Conditions
Explore the condition pages connected to this study.